Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 2;8(4):640.
doi: 10.3390/vaccines8040640.

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Mikhail P Kostinov  1   2 , Elena A Latysheva  3 , Aristitsa M Kostinova  3 , Nelly K Akhmatova  1 , Tatyana V Latysheva  3 , Anna E Vlasenko  4 , Yulia A Dagil  3 , Ekaterina A Khromova  1 , Valentina B Polichshuk  1
Affiliations

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Mikhail P Kostinov et al. Vaccines (Basel). .

Abstract

Background: Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice.

Methods: In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used.

Results: All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels.

Conclusion: Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.

Keywords: CVID; adjuvanted QIV; azoximer bromide; immunogenicity; influenza; seropositive/seronegative.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. The authors declare that the research was conducted in the absen+ce of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Seroprotection level 1 month after immunization given the initial level of antibodies in the group of healthy participants vaccinated with aQIV. Notes: *—statistically significant differences between groups
Figure 2
Figure 2
Seroconversion level 3 weeks after immunization given the initial level of antibodies in the group of healthy participants. Notes: *—statistically significant differences between groups.
Figure 3
Figure 3
GMR given the initial level of antibodies in the group of healthy participants. Notes: *—statistically significant differences between groups.
Figure 4
Figure 4
Geometric mean antibody titers (GMT) in the group of healthy participants given the initial level of antibodies. Notes: *—statistically significant differences between groups, #—statistically significant differences compared with the initial level.
See this image and copyright information in PMC

References

    1. Caini S., Huang Q.S., Ciblak M.A., Kusznierz G., Owen R., Wangchuk S., Henriques C.M.P., Njouom R., Fasce R.A., Yu H., et al. Epidemiological and virological characteristics of influenza B: Results of the Global Influenza B Study. Influ. Other Respir. Viruses. 2015;9:3–12. doi: 10.1111/irv.12319. - DOI - PMC - PubMed
    1. Kharit S.M., Rudakova A.M., Uskov A.N., Konovalova L.N., Lobzin Y.V. The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines. J. Infectol. 2017;9:17–22. doi: 10.22625/2072-6732-2017-9-2-17-22. - DOI
    1. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum. Vaccines Immunother. 2012;8:81–88. doi: 10.4161/hv.8.1.17623. - DOI - PMC - PubMed
    1. Beran J., Wertzova V., Honegr K., Kaliskova E., Havlíčková M., Havlík J., Jiřincová H., Van Belle P., Jain V., Innis B.L., et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: A concrete example. BMC Infect. Dis. 2009;9:2. doi: 10.1186/1471-2334-9-2. - DOI - PMC - PubMed
    1. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010;28:2149–2156. doi: 10.1016/j.vaccine.2009.11.068. - DOI - PubMed